Projects per year
My research is focussed on the extrinsic apoptotic pathway regulated by death receptors. In particular, my work investigates the predictive, prognostic and therapeutic relevance of the caspase 8 inhibitor FLIP and the inhibitor of apoptosis proteins (IAPs). We have shown that FLIP and IAPs are key regulators of death receptor-, chemotherapy- and radiation-induced apoptosis in a range of in vitro and in vivo cancer models. We are currently investigating ways in which FLIP can be targeted therapeutically.
The work of my group has indicated that FLIP and its partner protein procaspase-8 are frequently over-expressed together in many cancers, particularly those associated with inflammatory microenvironments, such as colorectal cancer, prostate cancer, non-small cell lung cancer and mesothelioma. High FLIP expression appears to be a potentially clinically useful biomarker for identifying patients most at risk of relapse and least likely to respond to standard chemotherapy. I also work on the development of predictive biomarkers for IAP-targeted therapeutics.
Another element of my research is to investigate fundamental aspects of death receptor biology. We recently characterized the critical protein-protein interactions between FLIP and its key binding partners FADD and procaspase 8 that occur at complexes formed by death receptors following death ligand binding. The mechanism that we propose is a unique, paradigm-changing model that is likely to have implications for other multimeric procaspase activating platforms such as the apoptosome (caspase 9). We have also recently uncovered two novel aspects of FLIP biology that we are currently investigating: (1) FLIP’s regulation by the ubiquitination-proteasome system via cullin RING E3 ubiquitin ligases; and (2) the role of nuclear FLIP in regulating DNA damage responses.
A major problem with current anti-cancer agents is their narrow therapeutic index. Working with Prof Chris Scott in the School of Pharmacy at Queen’s, we have developed tumour-targeted nanoparticle systems for delivery of anti-cancer drugs. This technology can reduce dose-limiting toxicities of a range of anti-cancer drugs, thereby widening their therapeutic windows. This technology also makes possible co-delivery of synergistic drug combinations and tumour-selective delivery of gold nanoparticles. As well as having novel radiotherapy and photothermic therapy applications, the gold nanoparticles, which we are developing with Prof Steven Bell (School of Chemistry), open up unique tumour imaging possibilities.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Dive into details
Select a country/territory to view shared publications and projects
11/08/2019 → …
Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive featuresFlanagan, D. J., Amirkhah, R., Vincent, D. F., Gunduz, N., Gentaz, P., Cammareri, P., McCooey, A. J., McCorry, A. M. B., Fisher, N. C., Davis, H. L., Ridgway, R. A., Lohuis, J., Leach, J. D. G., Jackstadt, R., Gilroy, K., Mariella, E., Nixon, C., Clark, W., Hedley, A., Markert, E. K., & 19 others, 31 Jan 2023, In: Nature Communications. 14, p. 522
Research output: Contribution to journal › Article › peer-reviewOpen Access
Longley, D. B. & The FEBS Journal Editorial Team, 07 Aug 2023, (Early online date) In: FEBS journal.
Research output: Contribution to journal › Editorial › peer-review
Evaluation of variable new antigen receptors (vNARs) as a novel Cathepsin S (CTSS) targeting strategySmyth, P., Ferguson, L., Burrows, J., Burden, R., Tracey, S., Herron, U., Kovaleva, M., Williams, R., Porter, A., Longley, D., Barelle, C. & Scott, C., 16 Nov 2023, (Accepted) In: Frontiers in Pharmacology.
Research output: Contribution to journal › Article › peer-review
Lawler, M., Sullivan, R., Abou-Alfa, G. K., McCloskey, K., Keatley, D., Feighan, J., Dahut, W., Mulroe, E., Ladner, R., Genead, M., Lowery, M., Gulley, J. L., Scott, C. J., Longley, D. B., Culhane, A., Gallagher, W. M., Orr, N., Chanock, S. J. & Gopal, S., Dec 2023, In: Journal of Cancer Policy. 38, 3 p., 100448.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile3 Downloads (Pure)
Increased Fusobacterium tumoural abundance affects immunogenicity in mucinous colorectal cancer and may be associated with improved clinical outcomeDuggan, W. P., Salvucci, M., Kisakol, B., Lindner, A. U., Reynolds, I. S., Dussmann, H., Fay, J., O'Grady, T., Longley, D. B., Ginty, F., Mc Donough, E., Slade, D. J., Burke, J. P. & Prehn, J. H. M., 12 May 2023, (Early online date) In: Journal of Molecular Medicine.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile4 Downloads (Pure)
- 1 Participation in workshop, seminar, course
Media coverage of the CCRCB (Wilson, McDade) led phase-I first in man trial of Lillys novel CDC7 inhibitor in p53 mutant cancers
1 item of Media coverage
Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation
Richard Kennedy (Participant), Denis Harkin (Participant), Patrick Johnston (Participant), Alison Hosey (Participant), Julia Miskelly (Participant), Margaret Murray (Participant), Jennifer Quinn (Participant), Colin James (Participant), Jude Mulligan (Participant), Peter Daly (Participant), Paul Mullan (Participant), Julie Mussen (Participant), Ultan McDermott (Participant), Richard Wilson (Participant) & Daniel Longley (Participant)
Impact: Health Impact, Quality of Life Impact